Kango Sujay
- SEC CIK
- 0001336503
No open-market purchases or sales filed in the past year.
Current role at each company
- DNTH Dianthus Therapeutics, Inc.Directoras of May 22, 2026
- LITS Lite Strategy, Inc.Directoras of Oct 12, 2023
- INFI Infinity Pharmaceuticals, Inc.Directoras of Mar 31, 2022
- XLRN Acceleron Pharma IncEVP, Chief Commercial Officeras of Nov 22, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Kango Sujay as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
XLRN Acceleron Pharma Inc
EVP, Chief Commercial Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 27, 2021 (view filing) | Sep 27 | Same day | Kango SujayEVP, Chief Commercial Officer | SSale | −5.00K | $175.00 | −$875.0K | −21.3%18.5K after | |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Kango SujayEVP, Chief Commercial Officer | SSale | −5.00K | $150.03 | −$750.1K | −21.3%18.5K after |